New Relic’s sale tells us much about the value of middling growth today


Share post:

Monitoring service New Relic this morning said it has agreed to be acquired by Francisco Partners and TPG for $6.5 billion in cash.

Shares of the company, which went public back in 2014, are up around 13.5% on the news.

The Exchange explores startups, markets and money.

Read it every morning on TechCrunch+ or get The Exchange newsletter every Saturday.

The deal is interesting because of its size, but we’re more interested in the insight it provides on the current state of the tech landscape as it pertains to valuations. Given the dry IPO climate, we are bereft of new data regarding exit values, so this deal is like a fresh, cool breeze on a sultry summer afternoon.

exchange banner sq grn plusNew Relic’s $87-per-share sale price gives it a valuation that’s less than seven times its current run-rate revenue. The question we have to answer is whether or not that price seems parsimonious, reasonable or indulgent given current market data and our valuation expectations based on recent private and public-market data.

This morning, we’ll start with a look at New Relic’s latest quarterly results, compare that information to its sale price, and then relate what we’ve learned back to everyone’s favorite corporate cohort: Richly-valued startups that have yet to leave their parents’ basements.

A business based on consumption

New Relic reported revenue of $242.6 million in the quarter ended June 30 (its fiscal first quarter), up 12% from a year earlier. The company has been shifting from a subscription model to a usage-based (consumption-based) pricing setup, and you can see that in the results: Consumption revenue increased 39% $213.9 million, while subscription revenue declined by 54% to $28.7 million.

Source link

Lisa Holden
Lisa Holden
Lisa Holden is a news writer for LinkDaddy News. She writes health, sport, tech, and more. Some of her favorite topics include the latest trends in fitness and wellness, the best ways to use technology to improve your life, and the latest developments in medical research.

Recent posts

Related articles

How to raise a Series A in today’s market

If you’re an early-stage founder, the crazy days of 2021 are a distant memory. Money is tight,...

Why we’re seeing so many seed-stage deals in fintech

Welcome back to The Interchange, where we take a look at the hottest fintech news of the previous...

SBF’s trial starts soon, but how did he — and FTX — get here?

The highly anticipated criminal trial for Sam Bankman-Fried, former CEO of bankrupt crypto exchange FTX, begins Tuesday...

A tale of two research institutes

If you’re lucky, once a year you get to put together a panel built on pure kismet....

Tinder goes ultra-premium, Amazon invests in Anthropic and Apple explains its new AirPods

It’s that time of the week again, folks — time for Week in Review (WiR), TechCrunch’s newsletter...

How much can artists make from generative AI? Vendors won’t say

As tech companies begin to monetize generative AI, the creators on whose work it is trained are...

Venture capital is opening the gates for defense tech

Welcome to the TechCrunch Exchange, a weekly startups-and-markets newsletter. It’s inspired by the daily TechCrunch+ column where...

Humane’s ‘AI Pin’ debuts on the Paris runway

You’d better believe that Humane is going to milk the media hype cycle for all it’s worth....